Led by Professor Catharine West, REQUITE's co-ordinator, The University of Manchester team created a method of selecting prostate cancer patients who would benefit from treatments which target oxygen deficient tumours. The study paves the way for better treatment of prostate cancer. To read the newsitem on AAAS and EurekAlert! click here.
Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy
The Final REQUITE Symposium Dissemination day is taking place in Manchester on 18th July 2018 (9:30-16:15, CityLabs). It will celebrate the successes of REQUITE and feedback to stakeholders on the impact of REQUITE and the availability of the REQUITE resource for future research. We hope to reach a wide audience including REQUITE patients, industry representatives, policy makers, clinicians, leading academic researchers, cancer patient groups and the public.
The 11th edition of the European Breast Cancer Conference (EBCC-11) took place from 21–23 March 2018 in Barcelona, Spain. The aim of the European Breast Cancer Conferences is to support the establishment of a European multidisciplinary platform for scientific exchanges on all aspects of breast cancer, from bench to bedside.
REQUITE abstract on hypofractionation among prostate cancer patients has been accepted as an oral presentation.
The 11th annual RGC meeting will take place on the 16th July (8:45-16:30) at the Manchester Cancer Research Centre - Manchester’s newest cancer research facility.
The first day of the Final REQUITE Symposium (17th July, 8:30-17:30, CityLabs) is open to REQUITE consortium members and invited guests. It will have an operational focus.
The Final REQUITE Symposium Dissemination day, (18th July, 9:30-16:15, CityLabs) will celebrate the successes of REQUITE and feedback to stakeholders on the impact of REQUITE and the availability of the REQUITE resource for future research. (Open to all)
ESMO is and continues to be a leading force of high-quality oncology education, a platform for immense international visibility for scientific research, and a proud contributor to continuous improvements in patient care.
For more information: website
ASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year.
Abstract Submission Site Opens: December 13, 2017
Abstract Submission Site Closes: February 14, 2018